Search

Your search keyword '"Day, D."' showing total 637 results

Search Constraints

Start Over You searched for: Author "Day, D." Remove constraint Author: "Day, D." Database Unpaywall Remove constraint Database: Unpaywall
637 results on '"Day, D."'

Search Results

2. 44P Exploratory analysis of peripheral pharmacodynamic (PD) biomarkers after sitravatinib (Sitra) and tislelizumab (TIS) in advanced solid tumors: SAFFRON-103

4. 1028P Preliminary phase I results from a first-in-human study of EMB-02, a PD-1xLAG-3 bispecific antibody, in patients (pts) with advanced solid tumors

5. Recommendations for the use of next-generation sequencing in patients with metastatic cancer in the Asia-Pacific region: a report from the APODDC working group

6. 202P A phase Ib/II study of OP-1250, an oral complete estrogen receptor (ER) antagonist (CERAN) and selective ER degrader (SERD) with palbociclib in patients (pts) with advanced or metastatic ER-positive, HER2-negative breast cancer (MBC)

7. Proton spin structure and generalized polarizabilities in the strong quantum chromodynamics regime

8. 380P Tumour naïve circulating tumour DNA (ctDNA) analysis in patients (pts) with resected colorectal cancer (CRC) in the phase III ASCOLT trial

9. 1614P Influence of cancer on COVID-19 vaccine beliefs, attitudes and uptake

10. Revealing the short-range structure of the mirror nuclei 3H and 3He

11. COVID-19 vaccine hesitancy in Australian patients with solid organ cancers

12. Measurement of R=σL/σT and the separated longitudinal and transverse structure functions in the nucleon-resonance region

13. P-94 Circulating-tumour DNA (ctDNA) detection using an ultra-sensitive next generation sequencing (NGS)-based assay in patients with resected colorectal cancer (CRC) in the phase III ASCOLT trial

15. 1P Sitravatinib + tislelizumab in patients with anti-PD-(L)1 refractory/resistant metastatic non-small cell lung cancer (NSCLC)

16. Measurement of the EMC effect in light and heavy nuclei

17. 153P Safety/tolerability and antitumor activity of sitravatinib plus tislelizumab (TIS) in patients with advanced platinum-resistant ovarian cancer (PROC)

18. Deeply virtual Compton scattering using a positron beam in Hall-C at Jefferson Lab

22. 1284P Sitravatinib + tislelizumab in patients with anti-PD-(L)1 refractory/resistant metastatic NSCLC

23. An experimental program with high duty-cycle polarized and unpolarized positron beams at Jefferson Lab

34. Phase I trial of alpelisib in combination with concurrent cisplatin-based chemoradiotherapy in patients with locoregionally advanced squamous cell carcinoma of the head and neck

35. 1057P Preliminary pharmacokinetics (PK), safety and efficacy of two dosing regimens of CS1003 (anti-PD-1) in solid tumours: 200 mg every 3-week (Q3W) and 400 mg every 6-week (Q6W) dosing

36. A versatile Johansson-type tender x-ray emission spectrometer

38. Anthropogenic Control Over Wintertime Oxidation of Atmospheric Pollutants

44. 7. Non-Hermitian Eigenvalue Problems

Catalog

Books, media, physical & digital resources